HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS

被引：3
|
作者：
Marcellin, P. [1 ]
Cooper, C. [2 ]
Balart, L. A. [3 ]
Larrey, D. G. [4 ]
Box, T. D. [5 ]
Yoshida, E. [6 ]
Lawitz, E. [7 ]
Buggisch, P. [8 ]
Ferenci, P. [9 ]
Weltman, M. [10 ]
Labriola-Tompkins, E. [11 ]
Le Pogam, S. [11 ]
Najera, I. [11 ]
Thomas, D. N. [11 ]
Hooper, G. [12 ]
Shulman, N. [13 ]
Zhang, Y. [13 ]
Navarro, M. T. [13 ]
Lim, C. Y. [13 ]
Brunda, M. [11 ]
Yetzer, E. S. [13 ]
Terrault, N. [14 ]
机构：
[1] Hop Beaujon, Clichy, France
[2] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada
[3] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA
[4] Montpellier Sch Med, Montpellier, France
[5] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Alamo Med Res, San Antonio, TX USA
[8] Asklepiosklin St Georg, Hamburg, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] Nepean Hosp, Penrith, NSW, Australia
[11] Roche, Nutley, NJ USA
[12] Roche, Welwyn Garden City, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61204-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1192
引用
收藏
页码：S472 / S472
页数：1
相关论文
共 50 条
  • [21] Sustained virological response (SVR) rate of 67% in HCV genotype 1-infected prior null responders treated with danoprevir/ritonavir (DNVr) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PegIFNα-2a/RBV)
    Gane, Edward J.
    Rouzier, Regine
    Wiercinska-Drapalo, Alicia
    Larrey, Dominique G.
    Bhardwaj, Rajinder
    Brennan, Barbara J.
    Giraudon, Mylene
    Le Pogam, Sophie
    Najera, Isabel
    Petric, Rosemary
    Jonathan Tran
    Zhang, Ying
    Smith, Patrick F.
    Yetzer, Ellen S.
    Shulman, Nancy
    HEPATOLOGY, 2012, 56 : 558A - 558A
  • [22] Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1.
    Berg, T
    von Wagner, M
    Hinrichsen, H
    Heintges, T
    Buggisch, P
    Goeser, T
    Rasenack, J
    Pape, GR
    Schmidt, WE
    Kallinowski, B
    Klinker, H
    Spengler, U
    Klapperich, B
    Popescu, M
    Zeuzem, S
    HEPATOLOGY, 2003, 38 (04) : 317A - 317A
  • [23] HIGH SUSTAINED VIROLOGICAL RESPONSE (SVR) RATE AFTER DANOPREVIR FOR ONLY 14 DAYS ASSOCIATED WITH PEG-INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS
    Larrey, D.
    Carenco, C.
    Guyader, D.
    Boyer, N.
    Benhamou, Y.
    Danielou, H.
    Pageaux, G. -P.
    Rouzier, R.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S481 - S481
  • [24] REFINED PREDICTION OF WEEK 12 RESPONSE AND SVR BASED ON THE VIROLOGICAL RESPONSE AT WEEK 4 IN HCV GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®)
    Marcellin, Patrick
    Reau, Nancy
    Ferenci, Peter
    Jensen, Donald M.
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1136A
  • [25] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [26] Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease
    Zeuzem, Stefan
    DeMasi, Ralph
    Foster, Graham R.
    Buti, Maria
    Laeuffer, Joerg M.
    Luo, Donghan
    Witek, James
    Rizzetto, Mario
    HEPATOLOGY, 2013, 58 : 1129A - 1129A
  • [27] Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Marcellin, Patrick
    Reau, Nancy
    Ferenci, Peter
    Hadziyannis, Stephanos
    Messinger, Diethelm
    Tatsch, Fernando
    Jensen, Donald
    JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1276 - 1282
  • [28] Treatment of patients with chronic hepatitis C with peginterferon alfa-2a (40KD) (Pegasys®) alone or in combination with ribavirin results in long-lasting sustained virological response.
    Swain, M
    Lai, MY
    Shiffmann, ML
    Cooksley, WGE
    Abergel, A
    Diago, M
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 598A - 598A
  • [29] Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection
    Marcellin, Patrick
    Cooper, Curtis
    Balart, Luis
    Larrey, Dominique
    Box, Terry
    Yoshida, Eric
    Lawitz, Eric
    Buggisch, Peter
    Ferenci, Peter
    Weltman, Martin
    Labriola-Tompkins, Emily
    Le Pogam, Sophie
    Najera, Isabel
    Thomas, Denise
    Hooper, Gregory
    Shulman, Nancy S.
    Zhang, Ying
    Navarro, Mercidita T.
    Lim, Chin Yin
    Brunda, Michael
    Terrault, Norah A.
    Yetzer, Ellen S.
    GASTROENTEROLOGY, 2013, 145 (04) : 790 - +
  • [30] Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients
    Reddy, K. R.
    Messinger, D.
    Popescu, M.
    Hadziyannis, S. J.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (10) : 724 - 731
12345